AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

2025 wird das HQ in Vancouver fertig gestellt.

Das Volumen hat gefehlt. Gebe Bescheid wenn wir mit ordentlich Volumen drüber sind und stark abschließen.

Sollte ich mein Geld eines Tages wieder haben verkaufe ich sofort diesen Müll

Es gab eine sogenannte „positive“ Meinung von Motley Fool, die die Langfristigkeit und das Risiko betonte. Danke schön. '1. AbCellera Biologics (ABCL -5.29%), a Canadian biotech, focuses on developing antibody-based medicines. The drugmaker's stock price has plummeted by more than 90% since it went public in late 2020, reflecting the risk-averse environment of the broader markets over this period. However, some analysts believe that AbCellera's stock could bounce back by a whopping 212% in 2024. The main reason for this bullish outlook is the potential for AbCellera to secure one or more major collaboration deals soon. Still, AbCellera is an extremely risky investment because the company does not expect to start clinical trials for its two most advanced programs -- ABCL575 and ABCL635 -- until 2025. Patient investors, though, might be richly rewarded by buying and holding this antibody drug specialist for the long haul. After all, antibody-based medicines represent one of the largest and fastest growing segments of biopharmaceutical industry right now.'

Haben wir erreicht und fällt trotzdem wieder stark

BMO Capital analyst Evan Seigerman has reiterated their bullish stance on ABCL stock, giving a Buy rating on January 5. Evan Seigerman has given his Buy rating due to a combination of factors surrounding AbCellera Biologics’s prospects and strategies. Despite not securing a partner for their T-cell engager (TCE) program in 2023, management has a strong conviction that a partnership will be forged in 2024, based on the impressive capabilities of their TCE assets and the demonstrated interest from the pharmaceutical industry in such technologies. Seigerman’s confidence stems from the fact that there has been a trend towards acquisitions and development of TCE assets by major pharmaceutical companies, which suggests a favorable environment for AbCellera to enter into a lucrative deal. Furthermore, the focus on internal pipeline updates, particularly for ABCL575 and ‘635, is anticipated to be a major catalyst for the company. The shift in strategy to prioritize the advancement of internal assets has been viewed positively by Seigerman, as it has the potential to significantly enhance shareholder value. While breakthroughs in AI drug development are considered an important aspect of the company’s future, the expectation is that these will take longer to materialize, suggesting a more measured but persistent approach to innovation. In another report released on January 5, KeyBanc also maintained a Buy rating on the stock with a $8.00 price target. https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-abcellera-biologics-amid-positive-tce-program-prospects-and-strategic-pipeline-focus?mod=mw_quote_news#google_vignette

Wenn wir 5,40$ erklimmen und halten, dann steigt das hier schneller als die meisten auf dem Schirm haben.

Mal sehen was 2024 passieren wird ich weiss es jetzt schon kurs kommt unter 3 Euro

+8 % verstörend!

Abcellera ist ein relativ kleines Unternehmen das noch 800 miljonen bar Geld besitzt. Es fangt gerade an statt gameover.

Abcellera ist gameover

'KeyBanc initiates coverage of AbCellera Biologics with an overweight rating as part of new coverage of digital biotech drug discovery sector' Aber Ziel nur 6 $.

Leerink Partners analyst Puneet Souda maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) on November 28. The company’s shares closed yesterday at $4.71. Souda covers the Healthcare sector, focusing on stocks such as 908 Devices, Illumina, and Bio-Techne. According to TipRanks, Souda has an average return of -8.7% and a 39.58% success rate on recommended stocks. AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $24.00. https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-buy-rating-on-abcellera-biologics-abcl-2?mod=mw_quote_news

Interessanter Webcast der Konferenz von Piper Sandler. Habe noch nachgekauft. Heute ist das Volumen hoch, also die Leute haben es verfolgt??

Gap bei 4$.